Focus on high-risk DTC patients: High postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival

Clinical Nuclear Medicine

Volumn 38, Issue 1, 2013, Pages 18-24

  Piccardo, Arnoldo ^a   Arecco, Federico ^b   Puntoni, Matteo ^a   Foppiani, Luca ^a   Cabria, Manlio ^a   Corvisieri, Stefania ^b   Arlandini, Anselmo ^a   Altrinetti, Vania ^a   Bandelloni, Roberto ^a   Orlandi, Fabio ^b  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

ablation Tg; High risk differentiated thyroid cancer; overall survival; positive predictive value; progression free survival; radioiodine therapy

Indexed keywords

IODINE 131; THYROGLOBULIN;

ABLATION THERAPY; ADULT; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RADIOISOTOPE THERAPY; RECURRENCE RISK; RISK ASSESSMENT; THYROIDECTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE CARE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 84871666052     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318266d4d8     Document Type: Article

References (21)

1. Schlumberger M, Pacini F, Wiersinga WM, et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol. 2004;151:539-548. (Pubitemid 39562507)
2. Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341-1349.
3. Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:1440-1445.
4. Polachek A, Hirsch D, Tzvetov G, et al. Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer. J Endocrinol Invest. 2011;34:855-860.
5. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
6. Pacini F, Schlumberger M, Dralle H, et al European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803. (Pubitemid 43997716)
7. Voutilainen PE, Siironen P, Franssila KO, et al. AMES, MACIS and TNM prognostic classifications in papillary thyroid carcinoma. Anticancer Res. 2003;23:4283-4288. (Pubitemid 37474934)
8. Lo CY, Chan WF, Lam KY, et al. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. Ann Surg. 2005;242: 708-715.
9. Brierley JD, Panzarella T, Tsang RW, et al. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer. 1997;79:2414-2423. (Pubitemid 27251027)
10. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83:1012-1021. (Pubitemid 28401936)
11. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91: 313-319. (Pubitemid 43069155)
12. Mazzaferri EL, Robbins RJ, Spencer A, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-1441. (Pubitemid 36623351)
13. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:150-157.
14. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50:122S-150S.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
16. Piccardo A, Arecco F, Morbelli S, et al. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer. J Endocrinol Invest. 2010;33:83-87.
17. Sipos JA, Mazzaferri EL. The therapeutic management of differentiated thyroid cancer. Expert Opin Pharmacother. 2008;9:2627-2637.
18. Castagna MG, Maino F, Cipri C, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), as better outcome predictivity in differentiated thyroid cancer patient. Eur J Endocrinol. 2011;165:441-446.
19. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 1996;37:598-605. (Pubitemid 126618447)
20. Tamilia M, Al-Kahtani N, Rochon L, et al. Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma. Nucl Med Commun. 2011;32:212-220.
21. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91:498-505. (Pubitemid 43236915)